To the editor
We read with interest the article by Iwata et al.1 in the February 2000 issue of Nature Medicine suggesting a major degrading catabolic pathway for Alzheimer amyloid β-peptide (Aβ) in brain. Our own work, however, has indicated that, in addition to production of the peptide, transport of Aβ across the microvascular endothelium (that is, the site of the blood–brain barrier) is essential in controlling Aβ levels in the brain2,3.
The physiological relevance of degradation mechanisms of Aβ described by Iwata et al.1 remains unclear, as the peptide was studied at very high concentrations of about 240 μm/l, which may impair blood–brain barrier integrity4,5. It is likely that Aβ at a concentration of 240 μm/l will cause plasma leakage into brain tissue. The size of the spot of Evans blue dye in the hippocampus and along the needle track shown by Iwata et al. (ref. 1, Fig. 1d) may translate into a volume of about 20–30 μl, much larger than the reported infusion volume of 0.5 μl. The invasive nature of the acute placement of 26-gauge needle used by Iwata et al.1 very likely damages the blood–brain barrier. There is injury to blood vessels and microbleeding. Also, staining along the needle track indicates substantial reflux of injected material back to subarchnoid space, where contamination with cerebrospinal fluid is obvious. It is essential to place a small 33-gauge guiding cannula at least 3–5 days before infusing peptides to allow the tissue to recover from the trauma.
Finally, the affinity of neprilysin for its physiological substrates (such as enkephalins, tachykinins and atrial natriuretic peptide) and/or different synthetic peptides is in the low millimolar to micromolar range6. Normal levels of Aβ in the brain are in the low nanomolar ranges. Even in transgenic models of brain amyloidosis, brain levels of Aβ range from 40 nm/kg to 250 nm/kg from 3 to 12 months7. Several cell surface receptors in brain endothelial cells, microglia and/or neurons, including the receptor specific for advanced glycosylation end-products (RAGE), the scavenger type A receptor (SR-A; refs. 2,8), LRP-1 (low density lipoprotein receptor related protein) (ref. 9) and LRP-2 (ref. 3) bind Aβ with high nanomolar affinity directly (RAGE and SR-A) or indirectly (LRP-1 and LRP-2) through ligands such as α2M and apolipoproteins E and J, which act as high-affinity transport binding proteins for Aβ. Thus, in the intact brain, Aβ probably binds to several high-affinity cell surface receptors and/for binding proteins before being recognized by potential degrading enzymes.
References
Iwata, N. et al. Identification of the major Aβ1–42-degrading catabolic pathway in brain parenchyma: Suppression leads to biochemical and pathological deposition. Nature Med. 6, 143–150 (2000).
Mackic, J.B. et al. Human blood–brain barrier receptors for Alzheimer's amyloid β 1–40. Asymmetrical binding, endocytosis, and transcytosis at the apical side of brain microvascular endothelial cell monolayer. J. Clin. Invest. 102, 734–743 (1998).
Zlokovic, B.V. et al. Glycoprotein 330/megalin: probable role in receptormediated transport of apolipoprotein J alone and in a complex with Alzheimer disease amyloid β at the blood-brain and blood-cerebrospinal fluid barriers. Proc. Natl. Acad. Sci. USA 93, 4229– 4234 (1996).
Blanc, E.M., Toborek, M., Mark, R.J., Hennig, B. & Mattson, M.P. Amyloid β-peptide induces cell monolayer albumin permeability, impairs glucose transport, and induces apoptosis in vascular endothelial cells. J. Neurochem. 68, 1870 –1881 (1997).
Thomas, T., Thomas, G., McLendon, C. & Sutton, T & Mullan, M. β-amyloid-mediated vasoactivity and vascular endothelial damage. Nature. 380, 168–171 (1996).
Hersh, L.B. & Morihara, K. Comparison of subsite specificity of the mammalian neutral endopeptidase 24.11 (enkephalinase) to the bacterial neutral endopeptidase thermolysin. J. Biol. Chem. 261 , 6433–6437 (1986).
Hsiao K. et al. Correlative memory deficits, Aβ elevation, and amyloid plaques in transgenic mice. Science 274, 99– 102 (1996).
Yan, SD, et al. RAGE and amyloid-β peptide neurotoxicity in Alzheimer's disease . Nature 382, 685–691 (1996).
Narita, M., Holtzman, D.M., Schwartz, A.L. & Bu, G. α2-macroglobulin complexes with and mediates the endocytosis of β-amyloid peptide via cell surface low-density lipoprotein receptor-related protein. J. Neurochem. 69, 1904– 1011 (1997).
Permanne, B. et al. Aβ40 and Aβ42 clearance in a transgenic mouse model expressing human ApoE3 and ApoE4. Soc. Neurosci. Abstr. 25, 1058 (1999).
Jarret, J.T. & Lansbury, P.T. Jr. Seeding “one-dimensional crystallization” of amyloid: a pathogenic mechanism of Alzheimer's disease and scrapie? Cell 73, 1055– 1058 (1993).
Hardy, J. Amyloid, the presenilins and Alzheimer's disease. Trends Neurosci. 20, 154–159 ( 1997).
Selkoe, D.J. The cell biology of β-amyloid precursor protein and presenilin in Alzheimer's disease. Trends Cell Biol. 8, 447– 453 (1998).
Price, D.L., Tanzi, R.E., Borchelt, D.R. & Sisodia, S.S. Alzheimer's disease: genetic studies and transgenic models. Annu. Rev. Genet. 32, 461–493 (1998).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Zlokovic, B., Yamada, S., Holtzman, D. et al. Clearance of amyloid β-peptide from brain: transport or metabolism? . Nat Med 6, 718 (2000). https://doi.org/10.1038/77397
Issue Date:
DOI: https://doi.org/10.1038/77397
This article is cited by
-
Altered dynamics of glymphatic flow in a mature-onset Tet-off APP mouse model of amyloidosis
Alzheimer's Research & Therapy (2023)
-
Microglia prevent beta-amyloid plaque formation in the early stage of an Alzheimer’s disease mouse model with suppression of glymphatic clearance
Alzheimer's Research & Therapy (2020)
-
Inhibition of Aquaporin 4 Decreases Amyloid Aβ40 Drainage Around Cerebral Vessels
Molecular Neurobiology (2020)
-
Magnesium Reduces Blood-Brain Barrier Permeability and Regulates Amyloid-β Transcytosis
Molecular Neurobiology (2018)
-
Amyloid beta: structure, biology and structure-based therapeutic development
Acta Pharmacologica Sinica (2017)